Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
Caleb Monroe
Press Releases

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics has submitted a Biologics License Application to the U.S. FDA for accelerated approval of z-rostudirsen (DYNE-251), a treatment targeting Duchenne Muscular Dystrophy patients amenable to exon 51 skipping. The submission is based on significant results from the DELIVER trial showing increased dystrophin production and functional im…

DYN
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2026
Nina Shah
Press Releases

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics announced multiple presentations at the 2026 CMSC annual meeting highlighting clinical and real-world data supporting BRIUMVI® (ublituximab-xiiy) as an effective treatment for relapsing forms of multiple sclerosis (RMS). New Phase 4 ENABLE study results demonstrate significant improvements in patient-reported outcomes and sustained …

TGTX
Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design
May 26, 2026
Jordan Park
Press Releases

Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

Streamex Corp. (NASDAQ: STEX), a technology company specializing in tokenization of real-world assets, announced the appointment of Kori Handy as Vice President of Product and Design. With 18 years of fintech and SaaS experience, Handy will lead the transformation of Streamex’s GLDY platform and future products to improve user experience and accele…

STEX
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
May 26, 2026
Priya Menon
Press Releases

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Pharma announced positive independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study demonstrating statistically significant genuine neural recovery with NVG-291 in chronic tetraplegia patients. 100% of treated subjects were responders versus 10% placebo, supporting NVG-291 as a potentially best-in-class restora…

NGEN
Global-e to Enhance Logistics Offering with Acquisition of Passport, a US-based e-Commerce Logistics and Solutions Company
May 26, 2026
Marcus Reed
Press Releases

Global-e to Enhance Logistics Offering with Acquisition of Passport, a US-based e-Commerce Logistics and Solutions Company

Global-e Online Ltd., a leading global direct-to-consumer e-commerce platform, announced its definitive agreement to acquire Passport Global Inc., a US-based cross-border e-commerce logistics company. The acquisition aims to deepen Global-e's logistics and trade compliance capabilities, improve the post-purchase experience, and expand service offer…

GLBE
California Resources Corporation Achieves First CO₂ Injection at Carbon TerraVault I, a Major Milestone for Carbon Management in California
May 26, 2026
Sofia Navarro
Press Releases

California Resources Corporation Achieves First CO₂ Injection at Carbon TerraVault I, a Major Milestone for Carbon Management in California

California Resources Corporation (NYSE: CRC) announced the first CO2 injection at its Carbon TerraVault I project, marking the launch of California's first operational carbon capture and storage (CCS) initiative. Located at the Elk Hills Field in Kern County, the project stores CO2 underground in depleted reservoirs, supporting California's carbon …

CRC
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 26, 2026
Derek Hwang
Press Releases

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics has secured up to $150 million in non-dilutive financing from K2 HealthVentures, including an initial $50 million tranche, extending its cash runway into 2028. The funding supports advancement of its lead cell therapy candidate Descartes-08 through multiple clinical programs targeting autoimmune diseases such as myasthenia gr…

RNAC
Appian Corporation to Present in Upcoming Investor Conferences
May 26, 2026
Leila Farooq
Press Releases

Appian Corporation to Present in Upcoming Investor Conferences

Appian Corporation announced that CFO Serge Tanjga will present at the TD Cowen Technology, Media & Telecom Conference and the William Blair Growth Stock Conference in late May and early June 2026. Both presentations will be webcast live and later available for replay. The company specializes in process automation technology for large enterprises a…

APPN
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
Nina Shah
Press Releases

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

Olema Pharmaceuticals announced a clinical trial collaboration with Bayer to evaluate the investigational KAT6 inhibitor OP-3136 in combination with Bayer's darolutamide in metastatic castration-resistant prostate cancer. The Phase 1b/2 study will enroll approximately 36 patients and aims to assess safety, tolerability, and preliminary anti-tumor a…

OLMA
REalloys Reports Progress on Commercial Agreements with the Saskatchewan Research Council; Exclusive Heavy Rare Earth Supply Chain on Track Ahead of 2027 Statutory Deadline
May 26, 2026
Avery Klein
Press Releases

REalloys Reports Progress on Commercial Agreements with the Saskatchewan Research Council; Exclusive Heavy Rare Earth Supply Chain on Track Ahead of 2027 Statutory Deadline

REalloys Inc. announced significant progress on its commercial agreements with the Saskatchewan Research Council (SRC) to upgrade and expand SRC's rare earth processing facility. The company committed $20.6 million toward facility upgrades to increase production capacity of key rare earth metals such as Neodymium-Praseodymium, Dysprosium, and Terbi…

ALOY
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 26, 2026
Sofia Navarro
Press Releases

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics announced that the U.S. FDA has granted their appeal following the Formal Dispute Resolution process regarding their Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for treating neovascular age-related macular degeneration (nAMD). The FDA recognizes substantial evidence of effectiveness from clinical tri…

OTLK
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
May 26, 2026
Nina Shah
Press Releases

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting

Tonix Pharmaceuticals disclosed results from a comprehensive retrospective U.S. real-world claims analysis involving over 261,000 fibromyalgia patients, emphasizing the high comorbidity burden and extensive healthcare resource utilization associated with the condition. The company recently commercialized TONMYA®, a novel non-opioid analgesic approv…

TNXP
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
May 26, 2026
Derek Hwang
Press Releases

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial evaluating JADE101, a monoclonal antibody targeting APRIL, in patients with immunoglobulin A nephropathy (IgAN). JADE101 aims to reduce pathogenic IgA production, offering a potentially effective and convenient treatment for this chronic autoimmune …

JBIO
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
May 26, 2026
Derek Hwang
Press Releases

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Corbus Pharmaceuticals announced updated positive clinical results from its Phase 1/2 trial of CRB-701 (SYS6002), a next-generation Nectin-4 targeted antibody drug conjugate, showing robust efficacy in second-line oropharyngeal squamous cell carcinoma and cervical cancer. The treatment demonstrated confirmed objective response rates of 42.9% in OPS…

CRBP
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
May 26, 2026
Maya Rios
Press Releases

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

Axsome Therapeutics announced presentations of new clinical data for AUVELITY, its treatment for major depressive disorder, at the American Society of Clinical Psychopharmacology 2026 Annual Meeting. The data focus on efficacy in patients with anxious distress and real-world clinical outcomes, demonstrating the drug's potential benefits and expandi…

AXSM
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
May 26, 2026
Priya Menon
Press Releases

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

Climb Bio, a clinical-stage biotech company, announced it will present new clinical data for its immunotherapy candidates CLYM116 and budoprutug at the European Renal Association Congress 2026. CLYM116 targets APRIL to treat IgA nephropathy, with initial Phase 1 safety data to be shown, while budoprutug, an anti-CD19 antibody, is in Phase 2 trials …

CLYM
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
May 26, 2026
Sofia Navarro
Press Releases

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics announced an in-person Immunology Day event to showcase promising initial and updated clinical data from over 30 patients in systemic lupus erythematosus and rheumatoid arthritis studies using CLN-978 and Velinotamig, both T cell engager therapies. The company highlighted progress in multi-dose cohorts and shared plans for adv…

CGEM
AutoZone 3rd Quarter Total Company Same Store Sales Increase 3.9%; Domestic Same Store Sales Increase 4.1%; EPS of $38.07
May 26, 2026
Ajmal Hussain
Press Releases

AutoZone 3rd Quarter Total Company Same Store Sales Increase 3.9%; Domestic Same Store Sales Increase 4.1%; EPS of $38.07

AutoZone, Inc. reported an 8.4% increase in net sales to $4.8 billion for the third quarter ended May 9, 2026. Total company same store sales increased 3.9% (constant currency), driven by a 4.1% domestic same store sales growth. Operating profit rose 6.6% to $923.8 million, with diluted EPS increasing to $38.07 compared to $35.36 last year. The com…

AZO
CSW Industrials Reports Robust Fiscal 2026 Fourth Quarter with Record Quarterly and Full Year Results; Contractor Solutions Segment Returns to Positive Organic Growth in Fourth Quarter
May 26, 2026
Jordan Park
Press Releases

CSW Industrials Reports Robust Fiscal 2026 Fourth Quarter with Record Quarterly and Full Year Results; Contractor Solutions Segment Returns to Positive Organic Growth in Fourth Quarter

CSW Industrials announced record revenue and adjusted EBITDA for fiscal 2026, driven primarily by strategic acquisitions and solid organic growth in the Contractor Solutions and Specialized Reliability Solutions segments. Despite some reported EPS decline due to non-cash impairments and higher interest expenses, adjusted EPS increased by 6.9% year-…

CSW